RSV D486N-mut. fusion protein inh.
oral antiviral clinical candidate
from lower barrier to atropisomerism of lead
Bioorg. Med. Chem., Oct. 31, 2020
Taisho Pharmaceutical, Saitama, JP
“compound 60b”
1 min read
“compound 60b” (Taisho D486N mutant RSV fusion protein inhibitor clinical candidate)
Search By Structure
- LY3502970
- S64315
- daridorexant
- “peptide 78”
- BMS-986144
- MLT-985
- EB-42486
- “compound 4d”
- “compound 60b”
- “compound 15a”
- “compound 31”
- “compound 36”
- BCPyr
- “compound 4j”
Molecules of the Month
2023
2022
2021
2020